Experience
Incyte Corp.
Concert Pharmaceuticals, Inc.
Incyte Corp. brought in Finnegan to handle a request for rehearing after the Patent and Trademark Appeal Board (PTAB) denied institution of Incyte’s inter partes review (IPR) petition against a patent claiming deuterated versions of the active ingredient in Incyte’s FDA approved Jakafi® product (ruxolitinib). The original petition was not drafted by Finnegan. The PTAB agreed with the rehearing request, which claimed that the original decision applied an overly restrictive standard for the lead compound analysis and for the reason to combine the prior art and granted institution. The PTAB rarely grants rehearing requests or institutes trial after an original denial. Finnegan successfully represented Incyte as lead counsel during the trial phase of the IPR, after which the Board in its final written decision (FWD) found all challenged claims of the patent-at-issue to be unpatentable. Finnegan also represented appellee Incyte before the Federal Circuit and secured a unanimous affirmance of the PTAB’s obviousness determination.
Incyte Corp. v. Concert Pharmaceuticals, Inc., IPR2017-01256, PTAB, Judges Fitzpatrick, Hulse, Yang, Smith, Franklin
Sun Pharm. Indus., Inc. f/d/b/a Concert Pharmaceuticals, Inc. v. Incyte Corp., 19-2011, Fed. Cir., Judges Hughs, Linn, Stark
FedEx Corp. v. Intellectual Ventures II LLC
FedEx Corp.
Ajinomoto Co., Inc. et al. v. CJ Cheiljedang Corp. et al.
Ajinomoto Company, Inc. et al.
Finnegan client Capsugel prevails in one of the first U.S. post-grant proceedings
Capsugel Belgium NV
SAP prevails in first PTAB post-grant review decision
SAP America Inc.
Finnegan client AbbVie secures non-institution decisions for Humira® patents
AbbVie Biotechnology, Ltd
Finnegan secures a non-institution decision at the PTAB for Health Diagnostic Laboratory
Health Diagnostic Laboratory, Inc,
ClearOne, Inc. v. Shure Acquisition Holdings, Inc.
Shure Acquisition Holdings, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.